Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Aramchol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,987Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galmed reports results from ARMOR study showing improvements
    Galmed reports results from ARMOR study showing improvements

    04 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-results-from-the-open-label-part-of-the-armor-study-showing-improvements-in-histology-imaging-and-biomarkers-with-aramchol-301713284.html

    PR NEWSWIRE
    04 Jan 2023
    Share Share
    Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in Lung Fibrosis
    Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in Lung Fibrosis

    07 Jul 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-a-lung-fibrosis-model-301582307.html

    PRNEWSWIRE
    07 Jul 2022
    Share Share
    Galmed Continues to Drive Innovation with 3 New US Patents Granted for Aramchol
    Galmed Continues to Drive Innovation with 3 New US Patents Granted for Aramchol

    11 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-continues-to-drive-innovation-with-three-new-us-patents-granted-for-aramchol-and-its-meglumine-salt-301458242.html

    PRNEWSWIRE
    11 Jan 2022
    Share Share
    Galmed Provides +ve Data from ARMOR Study; Reports Q3 2021 Financial Results
    Galmed Provides +ve Data from ARMOR Study; Reports Q3 2021 Financial Results

    08 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-provides-additional-positive-data-from-the-open-label-part-of-armor-study-and-reports-third-quarter-2021-financial-results-301418394.html

    PRNEWSWIRE
    08 Nov 2021
    Share Share
    Results of Galmed's Phase 2b ARREST Trial Published in Nature Medicine
    Results of Galmed's Phase 2b ARREST Trial Published in Nature Medicine

    11 Oct 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/results-of-galmeds-phase-2b-arrest-trial-of-aramchol-published-in-nature-medicine-301396857.html

    PRNEWSWIRE
    11 Oct 2021
    Share Share
    MHRA Agrees with Galmed's Plan to use Aramchol meglumine in Phase 3 ARMOR study
    MHRA Agrees with Galmed's Plan to use Aramchol meglumine in Phase 3 ARMOR study

    16 Aug 2021

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mhra-agrees-with-galmeds-plan-to-use-aramchol-meglumine-in-the-randomized-double-blind-placebo-controlled-part-of-the-phase-3-armor-study-301355683.html

    PR NEWSWIRE
    16 Aug 2021
    Share Share